Cancer Cell
Volume 40, Issue 6, 13 June 2022, Pages 590-591
LetterActivity of AZD7442 (tixagevimab-cilgavimab) against Omicron SARS-CoV-2 in patients with hematologic malignancies
Under an Elsevier user license
open archive
Cited by (0)
- 8
These authors contributed equally
© 2022 Elsevier Inc.